Lantern Pharma Inc LTRN

NAS: LTRN | ISIN: US51654W1018   14/11/2024
3,490 USD (-1,13%)
(-1,13%)   14/11/2024
Grafiek Lantern Pharma Inc Grafiek Lantern Pharma Inc

Lantern Pharma Inc in het nieuws

3 mei 2023 · Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial · Persbericht

12 mei 2022 · Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month · Persbericht

3 mei 2022 · Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights · Persbericht

26 april 2022 · Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors · Persbericht

22 april 2022 · Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET · Persbericht

22 maart 2022 · Lantern Pharma Announces Extension of Existing Share Repurchase Program · Persbericht

14 maart 2022 · Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting · Persbericht

10 maart 2022 · Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights · Persbericht

3 maart 2022 · Lantern Pharma Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022 · Persbericht

15 februari 2022 · Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio · Persbericht

Profiel Lantern Pharma Inc

Commerciële diensten
Diverse commerciële diensten
Fabricage van farmaceutische preparaten
Farmaceutica
Gezondheidstechnologie
Productie

Werknemers: 25

Mijn selecties